It is indeed valid to understand things from a valuation point of view.
The doubt is not the business, but simply whether the market has been giving too rosy of a future image for the company BASED on the current valuation.
My aim is to simply understand “Why?”. Even though most replies to my query have been biased investors (as mentioned by their disclosures), you all have shared some interesting points.
Like I mentioned before, the issue is NOT with the company, BUT the market perception Hitesh.
If ML & IT is not an apple to apple comparison, so is Pharma. Also, again, I emphasis, my query is about valuations and not the company and the demand for its product or its future prospects.
| Subscribe To Our Free Newsletter |
